Manfred Schedlowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Manfred Schedlowski has a total of 196 co-authors. Here are the top co-authors by number of shared publications:
- Harald Engler
Institute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
26 shared publications - Sven Benson
Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
13 shared publications - Martin Hadamitzky
Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
11 shared publications - Laura Lückemann
Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, 45122 Essen, Germany
6 shared publications Sigrid Elsenbruch
6 shared publications- Susann Hetze
Department of Neurosurgery and Spine Surgery, Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, Essen, Germany
6 shared publications
Latest Publications
- Open Access
- 21 November 2025
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 180, 106486
Between care and contagion: Insights from the endotoxin model into the social facets of sickness
- 21 November 2025
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 180, 106486
Open AccessBetween care and contagion: Insights from the endotoxin model into the social facets of sickness
- Open Access
- 13 November 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (11) , e70399
Modulating Placebo Effects in Clinical Trials: Study Team Briefing to Optimize Drug–Placebo Differences
Clinical trials often face challenges with placebo effects that can mask actual drug effects. We evaluated whether briefing the study team members on placebo mechanisms influenced analgesia. In this study, we compared the analgesic effects of oxycodone and placebo in three groups of 32 subjects. The groups were treated by an untrained study team ( Arm A ), a team trained to maximize ( Arm B ) and a team trained to minimize placebo effects ( Arm C ). The primary outcome was the reduction of pain during the cold pressor test, assessed by the area under the pain curve of the visual analog scale before and after blinded administration of oxycodone or placebo. Oxycodone and placebo demonstrated the expected differences in pain reduction across all study arms. Briefing the study team did not significantly affect pain reduction or treatment expectation, regardless of treatment. However, treatment expectations were more pronounced with oxycodone compared to placebo, showing a positive correlation of expectation and treatment effect only in the oxycodone group, possibly reflecting the influence of unblinding due to adverse effects. These findings suggest that a brief training of the study team may not be sufficient to alter treatment expectations and placebo analgesia. This insight will inform future efforts to apply placebo research to optimize blinded trial design and drug treatments in clinical settings. Trial Registration: DRKS 00013586 (German Clinical Trials Register), registered on December, 22nd 2017; URL: https://www.drks.de/drks_web/setLocale_EN.do
- 13 November 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (11) , e70399
Open AccessModulating Placebo Effects in Clinical Trials: Study Team Briefing to Optimize Drug–Placebo Differences
Clinical trials often face challenges with placebo effects that can mask actual drug effects. We evaluated whether briefing the study team members on placebo mechanisms influenced analgesia. In this study, we compared the analgesic effects of oxycodone and placebo in three groups of 32 subjects. The groups were treated by an untrained study team ( Arm A ), a team trained to maximize ( Arm B ) and a team trained to minimize placebo effects ( Arm C ). The primary outcome was the reduction of pain during the cold pressor test, assessed by the area under the pain curve of the visual analog scale before and after blinded administration of oxycodone or placebo. Oxycodone and placebo demonstrated the expected differences in pain reduction across all study arms. Briefing the study team did not significantly affect pain reduction or treatment expectation, regardless of treatment. However, treatment expectations were more pronounced with oxycodone compared to placebo, showing a positive correlation of expectation and treatment effect only in the oxycodone group, possibly reflecting the influence of unblinding due to adverse effects. These findings suggest that a brief training of the study team may not be sufficient to alter treatment expectations and placebo analgesia. This insight will inform future efforts to apply placebo research to optimize blinded trial design and drug treatments in clinical settings. Trial Registration: DRKS 00013586 (German Clinical Trials Register), registered on December, 22nd 2017; URL: https://www.drks.de/drks_web/setLocale_EN.do
- Open Access
- 9 May 2025
- Published by Elsevier in NeuroImage
- Vol. 314, 121257
Impact of experimental inflammation on the neuronal processing of cardiac interoceptive signals and heart rate variability in humans
- 9 May 2025
- Published by Elsevier in NeuroImage
- Vol. 314, 121257
Open AccessImpact of experimental inflammation on the neuronal processing of cardiac interoceptive signals and heart rate variability in humans
- Open Access
- 1 June 2024
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 18, 1299-1310
“I Was Almost in Disbelief” - Qualitative Analysis of Experiences and Expectations Among Psoriasis Patients Undergoing Biologic Treatment with Secukinumab
Purpose: Psoriasis is a highly debilitating chronic inflammatory disease. Increased understanding of its pathophysiology has enabled development of targeted treatments such as biologics. Several medical treatments have been shown to be influenced by patients’ experiences and expectations. However, only little is known about patients’ experiences with and expectations towards biologics. Our objectives were to identify patients’ treatment experiences and treatment expectations and assess their trajectories over the course of treatment with the IL-17A inhibitor secukinumab. Moreover, we aimed to document effects of psoriasis, factors that influence symptomatology, and prior treatment experiences. Patients and Methods: We conducted semi-structured interviews with n = 24 patients with moderate-to-severe plaque psoriasis and employed a qualitative content analysis to derive thematic and evaluative codes. Findings were validated via peer debriefings with experienced dermatologists. Results: Patients reported burdensome physical and psychological psoriasis symptoms and identified factors that can improve or worsen symptomatology, including stress and self-efficacy. Prior treatment experiences were mostly negative. Past barriers to effective treatment included time constraints or limited access. Concerning secukinumab, patients initially expected complete to partial remission of symptoms and occurrence or absence of side effects. Closer inspection of expectations and experiences revealed three trajectories. For most patients, initial expectations were met and future expectations remained unchanged. For the other patients, however, the experience did not match their initial expectation. One group then adapted their future expectations according to their experience, while the other group did not. Conclusion: To our knowledge, this is the first qualitative study to assess expectations towards treatment effectiveness and side effects, their trajectories, and interplay with experiences among psoriasis patients. Our findings highlight the value of further research on the subject in order to optimize care for psoriasis patients and to learn more about the trajectories and influence of treatment expectations in general. Plain Language Summary: Patients’ expectations towards a certain treatment can influence how well it will work and whether side effects occur or not. Such effects have been shown for a wide range of conditions, including dermatological ones. For patients suffering from psoriasis, a chronic inflammatory skin disease, modern biologics offer promising treatment options. Therefore, modern biologics are likely associated with high expectations by patients. Yet, the roles of treatment expectations and the experiences of patients undergoing biologic treatment have only received little attention to date. With this qualitative study, we aimed to understand patients’ perspectives on these treatments, the symptoms they suffer from, expectations towards treatment effectiveness and side effects as well as treatment experiences in the past and over the course of treatment with a modern biologic. To this end, we conducted and transcribed interviews with 24 patients after several months of biologic treatment. We then analyzed interview transcripts to determine underlying categories and summarized these in a common framework. We found that patients’ debilitating physical and psychological symptoms were often not well controlled in past treatments. Still, patients had positive expectations with regard to biologic treatment. For a large group of patients, their actual experiences met their expectations, leaving them with unchanged expectations for the future. Another important finding was the good understanding of factors influencing their symptomatology that patients had, like stress and self-efficacy. The reported findings may aid doctors in their clinical work, to further improve care for psoriasis patients.
- 1 June 2024
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 18, 1299-1310
Open Access“I Was Almost in Disbelief” - Qualitative Analysis of Experiences and Expectations Among Psoriasis Patients Undergoing Biologic Treatment with Secukinumab
Purpose: Psoriasis is a highly debilitating chronic inflammatory disease. Increased understanding of its pathophysiology has enabled development of targeted treatments such as biologics. Several medical treatments have been shown to be influenced by patients’ experiences and expectations. However, only little is known about patients’ experiences with and expectations towards biologics. Our objectives were to identify patients’ treatment experiences and treatment expectations and assess their trajectories over the course of treatment with the IL-17A inhibitor secukinumab. Moreover, we aimed to document effects of psoriasis, factors that influence symptomatology, and prior treatment experiences. Patients and Methods: We conducted semi-structured interviews with n = 24 patients with moderate-to-severe plaque psoriasis and employed a qualitative content analysis to derive thematic and evaluative codes. Findings were validated via peer debriefings with experienced dermatologists. Results: Patients reported burdensome physical and psychological psoriasis symptoms and identified factors that can improve or worsen symptomatology, including stress and self-efficacy. Prior treatment experiences were mostly negative. Past barriers to effective treatment included time constraints or limited access. Concerning secukinumab, patients initially expected complete to partial remission of symptoms and occurrence or absence of side effects. Closer inspection of expectations and experiences revealed three trajectories. For most patients, initial expectations were met and future expectations remained unchanged. For the other patients, however, the experience did not match their initial expectation. One group then adapted their future expectations according to their experience, while the other group did not. Conclusion: To our knowledge, this is the first qualitative study to assess expectations towards treatment effectiveness and side effects, their trajectories, and interplay with experiences among psoriasis patients. Our findings highlight the value of further research on the subject in order to optimize care for psoriasis patients and to learn more about the trajectories and influence of treatment expectations in general. Plain Language Summary: Patients’ expectations towards a certain treatment can influence how well it will work and whether side effects occur or not. Such effects have been shown for a wide range of conditions, including dermatological ones. For patients suffering from psoriasis, a chronic inflammatory skin disease, modern biologics offer promising treatment options. Therefore, modern biologics are likely associated with high expectations by patients. Yet, the roles of treatment expectations and the experiences of patients undergoing biologic treatment have only received little attention to date. With this qualitative study, we aimed to understand patients’ perspectives on these treatments, the symptoms they suffer from, expectations towards treatment effectiveness and side effects as well as treatment experiences in the past and over the course of treatment with a modern biologic. To this end, we conducted and transcribed interviews with 24 patients after several months of biologic treatment. We then analyzed interview transcripts to determine underlying categories and summarized these in a common framework. We found that patients’ debilitating physical and psychological symptoms were often not well controlled in past treatments. Still, patients had positive expectations with regard to biologic treatment. For a large group of patients, their actual experiences met their expectations, leaving them with unchanged expectations for the future. Another important finding was the good understanding of factors influencing their symptomatology that patients had, like stress and self-efficacy. The reported findings may aid doctors in their clinical work, to further improve care for psoriasis patients.
- Open Access
- 14 October 2023
- Published by Elsevier in Comprehensive Psychiatry
- Vol. 127, 152431
The influence of psychological traits and prior experience on treatment expectations
- 14 October 2023
- Published by Elsevier in Comprehensive Psychiatry
- Vol. 127, 152431
Open AccessThe influence of psychological traits and prior experience on treatment expectations
- 21 November 2022
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 106, 15
Effects of peripheral cytokine blockade on endotoxin-induced cytokines changes in the cerebrospinal fluid
- 21 November 2022
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 106, 15
Effects of peripheral cytokine blockade on endotoxin-induced cytokines changes in the cerebrospinal fluid
- 21 November 2022
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 106, 39-40
Taste-immune conditioning with fingolimod (FTY720) as an unconditioned stimulus
- 21 November 2022
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 106, 39-40
Taste-immune conditioning with fingolimod (FTY720) as an unconditioned stimulus
- 21 November 2022
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 106, 6
Alleviating allergic skin responses - Preliminary data of a conditioning and open label placebo paradigm
- 21 November 2022
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 106, 6
Alleviating allergic skin responses - Preliminary data of a conditioning and open label placebo paradigm
- 21 November 2022
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 106, 39
Temporal dynamics and specificity of cytokine changes in blood, cerebrospinal fluid and brain tissue of endotoxemic rats
- 21 November 2022
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 106, 39
Temporal dynamics and specificity of cytokine changes in blood, cerebrospinal fluid and brain tissue of endotoxemic rats
- 19 July 2022
- Published by Springer Nature
- p. 1-12
Psychoneuroimmunologie in der Onkologie